BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34979570)

  • 21. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia.
    Duits LC; van der Wel MJ; Cotton CC; Phoa KN; Ten Kate FJW; Seldenrijk CA; Offerhaus GJA; Visser M; Meijer SL; Mallant-Hent RC; Krishnadath KK; Pouw RE; Tijssen JGP; Shaheen NJ; Bergman JJGHM
    Gastroenterology; 2017 Apr; 152(5):993-1001.e1. PubMed ID: 28012849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
    Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
    Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Utility of confocal laser endomicroscopy in identifying high-grade dysplasia and adenocarcinoma in Barrett's esophagus: a systematic review and meta-analysis.
    Gupta A; Attar BM; Koduru P; Murali AR; Go BT; Agarwal R
    Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):369-77. PubMed ID: 24535597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased detection of Barrett's esophagus-associated neoplasia using wide-area trans-epithelial sampling: a multicenter, prospective, randomized trial.
    Vennalaganti PR; Kaul V; Wang KK; Falk GW; Shaheen NJ; Infantolino A; Johnson DA; Eisen G; Gerson LB; Smith MS; Iyer PG; Lightdale CJ; Schnoll-Sussman F; Gupta N; Gross SA; Abrams J; Haber GB; Chuttani R; Pleskow DK; Kothari S; Goldblum JR; Zhang Y; Sharma P
    Gastrointest Endosc; 2018 Feb; 87(2):348-355. PubMed ID: 28757316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
    Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low Risk of High-Grade Dysplasia or Esophageal Adenocarcinoma Among Patients With Barrett's Esophagus Less Than 1 cm (Irregular Z Line) Within 5 Years of Index Endoscopy.
    Thota PN; Vennalaganti P; Vennelaganti S; Young P; Gaddam S; Gupta N; Lieberman D; Sampliner R; Falk GW; Mathur S; Kennedy K; Cash BD; Moawad F; Bansal A; Spaander MC; Bruno MJ; Vargo J; Sharma P
    Gastroenterology; 2017 Apr; 152(5):987-992. PubMed ID: 27988383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frequency of Barrett's neoplasia after initial negative endoscopy with biopsy: a long-term histopathological follow-up study.
    Vieth M; Schubert B; Lang-Schwarz K; Stolte M
    Endoscopy; 2006 Dec; 38(12):1201-5. PubMed ID: 17163319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum 25-Hydroxyvitamin D Levels and the Risk of Dysplasia and Esophageal Adenocarcinoma in Patients with Barrett's Esophagus.
    Thota PN; Kistangari G; Singh P; Cummings L; Hajifathalian K; Lopez R; Sanaka MR
    Dig Dis Sci; 2016 Jan; 61(1):247-54. PubMed ID: 26233550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Barrett's esophagus surveillance in a prospective Dutch multi-center community-based cohort of 985 patients demonstrates low risk of neoplastic progression.
    Klaver E; Bureo Gonzalez A; Mostafavi N; Mallant-Hent R; Duits LC; Baak B; Böhmer CJM; van Oijen AHAM; Naber T; Scholten P; Meijer SL; Bergman JJGHM; Pouw RE;
    United European Gastroenterol J; 2021 Oct; 9(8):929-937. PubMed ID: 34228885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Magnitude and Time-Trend Analysis of Postendoscopy Esophageal Adenocarcinoma: A Systematic Review and Meta-analysis.
    Sawas T; Majzoub AM; Haddad J; Tielleman T; Nayfeh T; Yadlapati R; Singh S; Kolb J; Vajravelu RK; Katzka DA; Wani S;
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):e31-e50. PubMed ID: 33901662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett's Esophagus-Related Neoplasia: A Feasibility Study.
    Everson M; Magee C; Alzoubaidi D; Brogden S; Graham D; Lovat LB; Novelli M; Haidry R
    Dig Dis Sci; 2019 Oct; 64(10):2815-2822. PubMed ID: 30982210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Esophageal adenocarcinoma in a first-degree relative increases risk for esophageal adenocarcinoma in patients with Barrett's esophagus.
    Tofani CJ; Gandhi K; Spataro J; Yoo J; Murphy M; Mohan N; Daitch Z; Shah A; Janowski R; Huntley C; Dabbish N; Keith S; Coben R; Cohen S; Kastenberg D; Infantolino A
    United European Gastroenterol J; 2019 Mar; 7(2):225-229. PubMed ID: 31080607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Miniprobe confocal laser microscopy for the detection of invisible neoplasia in patients with Barrett's oesophagus.
    Pohl H; Rösch T; Vieth M; Koch M; Becker V; Anders M; Khalifa AC; Meining A
    Gut; 2008 Dec; 57(12):1648-53. PubMed ID: 18755886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trimodal imaging-assisted endoscopic mucosal resection of early Barrett's neoplasia.
    Thomas T; Singh R; Ragunath K
    Surg Endosc; 2009 Jul; 23(7):1609-13. PubMed ID: 19296171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Probe-based confocal laser endomicroscopy compared with standard four-quadrant biopsy for evaluation of neoplasia in Barrett's esophagus.
    Bajbouj M; Vieth M; Rösch T; Miehlke S; Becker V; Anders M; Pohl H; Madisch A; Schuster T; Schmid RM; Meining A
    Endoscopy; 2010 Jun; 42(6):435-40. PubMed ID: 20506064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of progression in Barrett's esophagus indefinite for dysplasia: a systematic review and meta-analysis.
    Krishnamoorthi R; Mohan BP; Jayaraj M; Wang KK; Katzka DA; Ross A; Adler DG; Iyer PG
    Gastrointest Endosc; 2020 Jan; 91(1):3-10.e3. PubMed ID: 31421077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study.
    Verbeek RE; van Oijen MG; ten Kate FJ; Vleggaar FP; Schipper ME; Casparie MK; van Baal JW; Siersema PD
    Am J Gastroenterol; 2012 Apr; 107(4):534-42. PubMed ID: 22270082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis.
    Rastogi A; Puli S; El-Serag HB; Bansal A; Wani S; Sharma P
    Gastrointest Endosc; 2008 Mar; 67(3):394-8. PubMed ID: 18045592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patients With Barrett's Esophagus and Persistent Low-grade Dysplasia Have an Increased Risk for High-grade Dysplasia and Cancer.
    Kestens C; Offerhaus GJ; van Baal JW; Siersema PD
    Clin Gastroenterol Hepatol; 2016 Jul; 14(7):956-962.e1. PubMed ID: 26748222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of body mass index on the prevalence and progression of dysplasia in Barrett's esophagus: a retrospective analysis (.).
    Thota PN; Arora Z; Benjamin T; Pagadala M; Lopez R; Sanaka MR
    Scand J Gastroenterol; 2016 Nov; 51(11):1288-93. PubMed ID: 27460942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.